ES2589079T3 - Tecnología de amplificación de ácido nucleíco acelerado isotérmicamente - Google Patents
Tecnología de amplificación de ácido nucleíco acelerado isotérmicamente Download PDFInfo
- Publication number
- ES2589079T3 ES2589079T3 ES10725825.3T ES10725825T ES2589079T3 ES 2589079 T3 ES2589079 T3 ES 2589079T3 ES 10725825 T ES10725825 T ES 10725825T ES 2589079 T3 ES2589079 T3 ES 2589079T3
- Authority
- ES
- Spain
- Prior art keywords
- primer
- primers
- region
- segment
- mother
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003321 amplification Effects 0.000 title claims description 175
- 238000003199 nucleic acid amplification method Methods 0.000 title claims description 175
- 150000007523 nucleic acids Chemical class 0.000 title claims description 33
- 102000039446 nucleic acids Human genes 0.000 title claims description 31
- 108020004707 nucleic acids Proteins 0.000 title claims description 31
- 238000005516 engineering process Methods 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 175
- 108091093088 Amplicon Proteins 0.000 claims abstract description 166
- 239000002773 nucleotide Substances 0.000 claims abstract description 77
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 75
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 70
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 70
- 230000000295 complement effect Effects 0.000 claims abstract description 57
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 26
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 3
- 238000007397 LAMP assay Methods 0.000 claims description 63
- 230000002441 reversible effect Effects 0.000 claims description 58
- 230000008569 process Effects 0.000 claims description 40
- 239000000523 sample Substances 0.000 claims description 34
- 238000001514 detection method Methods 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 230000037452 priming Effects 0.000 claims description 13
- 208000011738 Lichen planopilaris Diseases 0.000 claims description 11
- 102100026358 Lipoma-preferred partner Human genes 0.000 claims description 11
- 238000005755 formation reaction Methods 0.000 claims description 11
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 10
- 238000005259 measurement Methods 0.000 claims description 9
- 244000005700 microbiome Species 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 6
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 6
- 235000011180 diphosphates Nutrition 0.000 claims description 6
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims description 5
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims description 5
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims description 5
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108060001084 Luciferase Proteins 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 235000003869 genetically modified organism Nutrition 0.000 claims description 4
- 229960003085 meticillin Drugs 0.000 claims description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 101000743006 Lactococcus lactis subsp. cremoris UPF0177 protein in abiGi 5'region Proteins 0.000 claims description 3
- 239000005089 Luciferase Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 3
- 238000011002 quantification Methods 0.000 claims description 3
- 206010067484 Adverse reaction Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 2
- 229930010555 Inosine Natural products 0.000 claims description 2
- 241001430197 Mollicutes Species 0.000 claims description 2
- PJKKQFAEFWCNAQ-UHFFFAOYSA-N N(4)-methylcytosine Chemical compound CNC=1C=CNC(=O)N=1 PJKKQFAEFWCNAQ-UHFFFAOYSA-N 0.000 claims description 2
- 108091028664 Ribonucleotide Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 230000006838 adverse reaction Effects 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- -1 for example Substances 0.000 claims description 2
- 229960003786 inosine Drugs 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 239000002336 ribonucleotide Substances 0.000 claims description 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims 2
- 238000001668 nucleic acid synthesis Methods 0.000 claims 2
- 101000794020 Homo sapiens Bromodomain-containing protein 8 Proteins 0.000 claims 1
- 101001006782 Homo sapiens Kinesin-associated protein 3 Proteins 0.000 claims 1
- 101000615355 Homo sapiens Small acidic protein Proteins 0.000 claims 1
- WGKGADVPRVLHHZ-ZHRMCQFGSA-N N-[(1R,2R,3S)-2-hydroxy-3-phenoxazin-10-ylcyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide Chemical compound O[C@H]1[C@@H](CCC[C@@H]1N1C2=CC=CC=C2OC2=C1C=CC=C2)NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 WGKGADVPRVLHHZ-ZHRMCQFGSA-N 0.000 claims 1
- 102100021255 Small acidic protein Human genes 0.000 claims 1
- 230000029918 bioluminescence Effects 0.000 claims 1
- 238000005415 bioluminescence Methods 0.000 claims 1
- 238000002848 electrochemical method Methods 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 55
- 108091028732 Concatemer Proteins 0.000 description 31
- 238000006073 displacement reaction Methods 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 230000007246 mechanism Effects 0.000 description 23
- 239000002157 polynucleotide Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- 241000186779 Listeria monocytogenes Species 0.000 description 13
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 241000282326 Felis catus Species 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 101000773513 Methanopyrus kandleri (strain AV19 / DSM 6324 / JCM 9639 / NBRC 100938) Uncharacterized protein MK0525 Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 6
- 230000003466 anti-cipated effect Effects 0.000 description 6
- 238000011901 isothermal amplification Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000186781 Listeria Species 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000001133 acceleration Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102000004523 Sulfate Adenylyltransferase Human genes 0.000 description 2
- 108010022348 Sulfate adenylyltransferase Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 101150008979 mecA gene Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 1
- 108700031821 Bacteria invA Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 101100107522 Mus musculus Slc1a5 gene Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101100489871 Rattus norvegicus Got2 gene Proteins 0.000 description 1
- 108700005711 Staphylococcus aureus SarH1 Proteins 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000011013 aquamarine Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0910302.9A GB0910302D0 (en) | 2009-06-15 | 2009-06-15 | Nucleic acid amplification |
| GB0910302 | 2009-06-15 | ||
| PCT/GB2010/001169 WO2010146349A1 (en) | 2009-06-15 | 2010-06-15 | Stem accelerated isothermal nucleic acid amplification technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2589079T3 true ES2589079T3 (es) | 2016-11-10 |
Family
ID=40940851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10725825.3T Active ES2589079T3 (es) | 2009-06-15 | 2010-06-15 | Tecnología de amplificación de ácido nucleíco acelerado isotérmicamente |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9410190B2 (enExample) |
| EP (1) | EP2443253B1 (enExample) |
| JP (2) | JP5907864B2 (enExample) |
| CN (1) | CN102652176B (enExample) |
| AU (1) | AU2010261541B2 (enExample) |
| CA (1) | CA2765406C (enExample) |
| ES (1) | ES2589079T3 (enExample) |
| GB (1) | GB0910302D0 (enExample) |
| WO (1) | WO2010146349A1 (enExample) |
| ZA (1) | ZA201109493B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2391732B1 (en) | 2009-01-30 | 2015-05-27 | Oxford Nanopore Technologies Limited | Methods using adaptors for nucleic acid constructs in transmembrane sequencing |
| EP2633071B1 (en) | 2010-10-27 | 2016-10-12 | President and Fellows of Harvard College | Compositions of toehold primer duplexes and methods of use |
| ES2537189T3 (es) * | 2011-05-24 | 2015-06-03 | Elitech Holding B.V. | Detección de estafilococos áureos resistentes a la meticilina |
| JP6298404B2 (ja) | 2011-07-25 | 2018-03-20 | オックスフォード ナノポール テクノロジーズ リミテッド | 膜貫通ポアを用いる二重鎖ポリヌクレオチド配列決定のためのヘアピンループ方法 |
| US11155860B2 (en) | 2012-07-19 | 2021-10-26 | Oxford Nanopore Technologies Ltd. | SSB method |
| GB201314695D0 (en) | 2013-08-16 | 2013-10-02 | Oxford Nanopore Tech Ltd | Method |
| CA2901545C (en) | 2013-03-08 | 2019-10-08 | Oxford Nanopore Technologies Limited | Use of spacer elements in a nucleic acid to control movement of a helicase |
| CN116334193A (zh) * | 2013-03-15 | 2023-06-27 | 赛拉诺斯知识产权有限责任公司 | 核酸扩增 |
| US10450595B2 (en) | 2013-03-15 | 2019-10-22 | Theranos Ip Company, Llc | Nucleic acid amplification |
| US9677981B2 (en) | 2013-03-15 | 2017-06-13 | 3M Innovative Properties Company | Sample concentrator and method of use |
| SG11201507273SA (en) | 2013-03-15 | 2015-10-29 | Theranos Inc | Nucleic acid amplification |
| WO2015019247A1 (en) * | 2013-08-09 | 2015-02-12 | Genebio Systems, Inc. | Dna amplification via scissor-like structures (dasl) |
| SG11201601611WA (en) | 2013-09-06 | 2016-04-28 | Theranos Inc | Systems and methods for detecting infectious diseases |
| CN103497947B (zh) * | 2013-09-13 | 2015-08-12 | 浙江国际旅行卫生保健中心 | 一种体外新型快速环介导等温扩增方法、体外检测甲型h1n1流感病毒的试剂及方法 |
| MX370616B (es) * | 2013-11-22 | 2019-12-17 | Theranos Ip Co Llc | Amplificacion de acidos nucleicos. |
| US11286519B2 (en) | 2013-12-11 | 2022-03-29 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| US10767222B2 (en) | 2013-12-11 | 2020-09-08 | Accuragen Holdings Limited | Compositions and methods for detecting rare sequence variants |
| US11859246B2 (en) | 2013-12-11 | 2024-01-02 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| WO2017062863A1 (en) | 2015-10-09 | 2017-04-13 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| GB201403096D0 (en) | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
| US10716587B2 (en) | 2014-06-13 | 2020-07-21 | Surgis Medical Llc | Surgical device with light |
| US10364458B2 (en) | 2014-07-16 | 2019-07-30 | Tangen Biosciences, Inc. | Isothermal methods for amplifying nucleic acid samples |
| EP3215260B1 (en) | 2014-11-03 | 2020-01-15 | Tangen Biosciences Inc. | Apparatus and method for cell, spore, or virus capture and disruption |
| US11639522B2 (en) | 2015-01-30 | 2023-05-02 | President And Fellows Of Harvard College | Microscope-free imaging |
| GB2550712B (en) * | 2015-02-26 | 2021-01-13 | Hitachi High Tech Corp | Method for constructing hairpin-containing nucleic acid molecules for nanopore sequencing |
| US10260090B2 (en) | 2015-07-16 | 2019-04-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Accelerated isothermal amplification of DNA |
| WO2017096322A1 (en) | 2015-12-03 | 2017-06-08 | Accuragen Holdings Limited | Methods and compositions for forming ligation products |
| EP4239079B1 (en) | 2016-02-17 | 2025-12-17 | President And Fellows Of Harvard College | Molecular programming tools |
| CN109511265B (zh) | 2016-05-16 | 2023-07-14 | 安可济控股有限公司 | 通过链鉴定改进测序的方法 |
| GB201609220D0 (en) | 2016-05-25 | 2016-07-06 | Oxford Nanopore Tech Ltd | Method |
| CN107488656B (zh) * | 2016-06-13 | 2020-07-17 | 陆欣华 | 一种核酸等温自扩增方法 |
| CN109844133A (zh) | 2016-08-15 | 2019-06-04 | 安可济控股有限公司 | 检测罕见序列变体的组合物和方法 |
| JP7116062B2 (ja) * | 2017-01-10 | 2022-08-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 多重化シグナル増幅 |
| EP3724322A1 (en) | 2017-12-14 | 2020-10-21 | Medicinal Genomics Corporation | Methods and kits for classifying cannabinoid production in cannabis plants |
| CN111630179B (zh) | 2018-01-26 | 2024-07-19 | 哈佛学院院长及董事 | 邻近检测方法和组合物 |
| GB201807793D0 (en) | 2018-05-14 | 2018-06-27 | Oxford Nanopore Tech Ltd | Method |
| WO2019241290A1 (en) | 2018-06-12 | 2019-12-19 | Accuragen Holdings Limited | Methods and compositions for forming ligation products |
| US12553080B2 (en) | 2021-06-14 | 2026-02-17 | Delta Electronics Int'l (Singapore) Pte Ltd | Lamp primer set and method for amplifying nucleic acids using the same |
| CN114045330B (zh) * | 2021-12-23 | 2024-02-09 | 川北医学院附属医院 | 一种基于滑动复制的核酸等温扩增方法 |
| CN118621045A (zh) * | 2024-08-14 | 2024-09-10 | 天健生物制药（天津）有限公司 | 基于lamp的鸟分枝杆菌检测的组合物和试剂盒 |
| WO2026050948A1 (zh) * | 2024-09-04 | 2026-03-12 | 深圳华大生命科学研究院 | 核酸文库的构建方法及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866336A (en) * | 1996-07-16 | 1999-02-02 | Oncor, Inc. | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| ES2327712T3 (es) * | 2000-09-19 | 2009-11-03 | Eiken Kagaku Kabushiki Kaisha | Procedimiento para sintetizar polinucleotidos. |
| WO2002090538A1 (en) | 2001-05-08 | 2002-11-14 | Eiken Kagaku Kabushiki Kaisha | Method of synthesizing nucleic acid |
| GB0218215D0 (en) | 2002-08-06 | 2002-09-11 | Tepnel Medical Ltd | Amplification of nucleic acids |
| EP1924713B1 (en) | 2005-08-24 | 2011-11-09 | Life Technologies Corporation | A method to quantify sirnas, mirnas and polymorphic mirnas |
| JP4580875B2 (ja) * | 2006-01-20 | 2010-11-17 | 株式会社東芝 | 核酸検出法のためのプライマーの設計方法 |
| JP2008029333A (ja) | 2006-07-03 | 2008-02-14 | Fujifilm Corp | 新規遺伝子増幅法に用いられるプライマー |
| EP2069540B1 (en) | 2006-10-09 | 2014-03-19 | Oxitec Limited | Methods for amplifying and detecting nucleic acid sequences |
| JP4490988B2 (ja) | 2007-04-26 | 2010-06-30 | 株式会社東芝 | 血清アミロイドａ１（ｓａａ１）の遺伝子型を検出するための核酸プライマーセット、キット、及び該プライマーセットを用いた検出方法 |
| US8748100B2 (en) | 2007-08-30 | 2014-06-10 | The Chinese University Of Hong Kong | Methods and kits for selectively amplifying, detecting or quantifying target DNA with specific end sequences |
-
2009
- 2009-06-15 GB GBGB0910302.9A patent/GB0910302D0/en not_active Ceased
-
2010
- 2010-06-15 CA CA2765406A patent/CA2765406C/en active Active
- 2010-06-15 EP EP10725825.3A patent/EP2443253B1/en active Active
- 2010-06-15 JP JP2012515553A patent/JP5907864B2/ja not_active Expired - Fee Related
- 2010-06-15 US US13/377,704 patent/US9410190B2/en active Active
- 2010-06-15 ES ES10725825.3T patent/ES2589079T3/es active Active
- 2010-06-15 AU AU2010261541A patent/AU2010261541B2/en not_active Ceased
- 2010-06-15 WO PCT/GB2010/001169 patent/WO2010146349A1/en not_active Ceased
- 2010-06-15 CN CN201080035868.5A patent/CN102652176B/zh active Active
-
2011
- 2011-12-22 ZA ZA2011/09493A patent/ZA201109493B/en unknown
-
2015
- 2015-10-09 JP JP2015201347A patent/JP6106732B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9410190B2 (en) | 2016-08-09 |
| US20120157326A1 (en) | 2012-06-21 |
| WO2010146349A1 (en) | 2010-12-23 |
| GB0910302D0 (en) | 2009-07-29 |
| EP2443253B1 (en) | 2016-06-08 |
| JP2012529904A (ja) | 2012-11-29 |
| CN102652176A (zh) | 2012-08-29 |
| CA2765406A1 (en) | 2010-12-23 |
| JP2016041070A (ja) | 2016-03-31 |
| JP5907864B2 (ja) | 2016-04-26 |
| ZA201109493B (en) | 2015-07-29 |
| CN102652176B (zh) | 2016-09-28 |
| AU2010261541B2 (en) | 2016-03-10 |
| AU2010261541A1 (en) | 2012-02-02 |
| JP6106732B2 (ja) | 2017-04-05 |
| EP2443253A1 (en) | 2012-04-25 |
| CA2765406C (en) | 2019-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2589079T3 (es) | Tecnología de amplificación de ácido nucleíco acelerado isotérmicamente | |
| ES2618127T3 (es) | Composiciones de dúplex de cebador de extremos cohesivos y métodos de uso | |
| ES2870626T3 (es) | Métodos de marcado molecular y bibliotecas de secuenciación | |
| Liu et al. | Validation of a quantitative method for real time PCR kinetics | |
| ES2927463T3 (es) | Diagnósticos basados en el sistema efector CRISPR | |
| ES2880335T3 (es) | Métodos y composiciones para la preparación rápida de bibliotecas de ácidos nucleicos | |
| KR20210104835A (ko) | 분자 진단을 위한 장치 및 방법 | |
| ES2707744T3 (es) | Métodos para detectar variantes de secuencia raras | |
| ES2754251T3 (es) | Secuencia cubierta de conversión de ADN y métodos de detección | |
| ES2655319T3 (es) | Método de detección de nucleótidos únicos | |
| ES2611592T3 (es) | Amplificación de ácidos nucleicos | |
| JP2013501508A5 (enExample) | ||
| JP2016500275A5 (enExample) | ||
| ES2950346T3 (es) | Detección mejorada de repeticiones homopoliméricas cortas | |
| ES2791280T3 (es) | Método de detección, composición y kit basados en reacciones en cascada de ADN amplificador de señal con extensión de la diana | |
| ES2729637T3 (es) | Amplificación de ácidos nucleicos | |
| CN102459626A (zh) | 核酸扩增方法 | |
| ES2879823T3 (es) | Amplificación de ácidos nucleicos | |
| ES2697401T3 (es) | Cebadores modificados para amplificación y detección de ácidos nucleicos | |
| Kim et al. | Enhancing multiplex detection capabilities of the Cas12a/blocker DNA system | |
| Meng et al. | Lineal DNA logic gate for microRNA diagnostics with strand displacement and fluorescence resonance energy transfer | |
| Chen et al. | Electrochemical biosensor based on hairpin DNA probe using 2-nitroacridone as electrochemical indicator for detection of DNA species related to chronic myelogenous leukemia | |
| ES2911458T3 (es) | Procedimiento para la detección de secuencias de ácido nucleico específicas | |
| JP2017538418A (ja) | 抗生物質耐性細菌を検出する方法および組成物 | |
| Ming et al. | Eliminating the secondary structure of targeting strands for enhancement of DNA probe based low-abundance point mutation detection |